194 related articles for article (PubMed ID: 34781870)
1. Fourth Generation of Synthetic Cannabinoid Receptor Agonists: A Review on the Latest Insights.
Malaca S; Busardò FP; Nittari G; Sirignano A; Ricci G
Curr Pharm Des; 2022; 28(32):2603-2617. PubMed ID: 34781870
[TBL] [Abstract][Full Text] [Related]
2. Fourth generation of synthetic cannabinoid receptor agonists: a summary on the latest insights.
Malaca S; Tini A; Umani Ronchi F
Acta Biomed; 2022 Jan; 92(6):e2021546. PubMed ID: 35075053
[TBL] [Abstract][Full Text] [Related]
3. The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances: Origins.
Banister SD; Connor M
Handb Exp Pharmacol; 2018; 252():165-190. PubMed ID: 29980914
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo pharmacology of nine novel synthetic cannabinoid receptor agonists.
Marusich JA; Gamage TF; Zhang Y; Akinfiresoye LR; Wiley JL
Pharmacol Biochem Behav; 2022 Oct; 220():173467. PubMed ID: 36154844
[TBL] [Abstract][Full Text] [Related]
5. Subtle Structural Modification of a Synthetic Cannabinoid Receptor Agonist Drastically Increases its Efficacy at the CB1 Receptor.
Yano H; Chitsazi R; Lucaj C; Tran P; Hoffman AF; Baumann MH; Lupica CR; Shi L
ACS Chem Neurosci; 2023 Nov; 14(21):3928-3940. PubMed ID: 37847546
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological evaluation of new generation OXIZID synthetic cannabinoid receptor agonists.
Patel M; Zheng X; Akinfiresoye LR; Prioleau C; Walker TD; Glass M; Marusich JA
Eur J Pharmacol; 2024 May; 971():176549. PubMed ID: 38561104
[TBL] [Abstract][Full Text] [Related]
7. Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists.
Chung EY; Cha HJ; Min HK; Yun J
Arch Pharm Res; 2021 Apr; 44(4):402-413. PubMed ID: 33811300
[TBL] [Abstract][Full Text] [Related]
8. The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects.
van Amsterdam J; Brunt T; van den Brink W
J Psychopharmacol; 2015 Mar; 29(3):254-63. PubMed ID: 25586398
[TBL] [Abstract][Full Text] [Related]
9. Differential activation of G protein-mediated signaling by synthetic cannabinoid receptor agonists.
Sachdev S; Banister SD; Santiago M; Bladen C; Kassiou M; Connor M
Pharmacol Res Perspect; 2020 Apr; 8(2):e00566. PubMed ID: 32101383
[TBL] [Abstract][Full Text] [Related]
10. Cannabinoid receptor activation potential of the next generation, generic ban evading OXIZID synthetic cannabinoid receptor agonists.
Deventer MH; Van Uytfanghe K; Vinckier IMJ; Reniero F; Guillou C; Stove CP
Drug Test Anal; 2022 Sep; 14(9):1565-1575. PubMed ID: 35560866
[TBL] [Abstract][Full Text] [Related]
11. Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists.
Patel M; Manning JJ; Finlay DB; Javitch JA; Banister SD; Grimsey NL; Glass M
Biochem Pharmacol; 2020 May; 175():113871. PubMed ID: 32088263
[TBL] [Abstract][Full Text] [Related]
12. The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonist New Psychoactive Substances: Evolution.
Banister SD; Connor M
Handb Exp Pharmacol; 2018; 252():191-226. PubMed ID: 30105473
[TBL] [Abstract][Full Text] [Related]
13. Metabolites of Synthetic Cannabinoid 5F-MDMB-PINACA Retain Affinity, Act as High Efficacy Agonists and Exhibit Atypical Pharmacodynamic Properties at CB1 Receptors.
Cabanlong CV; Russell LN; Fantegrossi WE; Prather PL
Toxicol Sci; 2022 Apr; 187(1):175-185. PubMed ID: 35201352
[TBL] [Abstract][Full Text] [Related]
14. Pharmacology, prevalence in Germany, and analytical data of cyclobutylmethyl- and norbornylmethyl-type synthetic cannabinoid receptor agonists.
Pulver B; Riedel J; Schönberger T; Halter S; Lucas T; Opatz T; Grafinger KE; Scheu M; Zschiesche A; Pütz M; Pützer K; Westphal F; Auwärter V
Drug Test Anal; 2023 Apr; 15(4):408-425. PubMed ID: 36541839
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological insights emerging from the characterization of a large collection of synthetic cannabinoid receptor agonists designer drugs.
Gioé-Gallo C; Ortigueira S; Brea J; Raïch I; Azuaje J; Paleo MR; Majellaro M; Loza MI; Salas CO; García-Mera X; Navarro G; Sotelo E
Biomed Pharmacother; 2023 Aug; 164():114934. PubMed ID: 37236027
[TBL] [Abstract][Full Text] [Related]
16. Functional evaluation of carboxy metabolites of synthetic cannabinoid receptor agonists featuring scaffolds based on L-valine or L-tert-leucine.
Wouters E; Mogler L; Cannaert A; Auwärter V; Stove C
Drug Test Anal; 2019 Aug; 11(8):1183-1191. PubMed ID: 31021521
[TBL] [Abstract][Full Text] [Related]
17. Assessment of select synthetic cannabinoid receptor agonist bias and selectivity between the type 1 and type 2 cannabinoid receptor.
Zagzoog A; Brandt AL; Black T; Kim ED; Burkart R; Patel M; Jin Z; Nikolaeva M; Laprairie RB
Sci Rep; 2021 May; 11(1):10611. PubMed ID: 34012003
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and
Cannaert A; Sparkes E; Pike E; Luo JL; Fang A; Kevin RC; Ellison R; Gerona R; Banister SD; Stove CP
ACS Chem Neurosci; 2020 Dec; 11(24):4434-4446. PubMed ID: 33253529
[TBL] [Abstract][Full Text] [Related]
19. Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB
Grafinger KE; Cannaert A; Ametovski A; Sparkes E; Cairns E; Banister SD; Auwärter V; Stove CP
Drug Test Anal; 2021 Jul; 13(7):1402-1411. PubMed ID: 33769699
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018.
Gamage TF; Barrus DG; Kevin RC; Finlay DB; Lefever TW; Patel PR; Grabenauer MA; Glass M; McGregor IS; Wiley JL; Thomas BF
Pharmacol Biochem Behav; 2020 Jun; 193():172918. PubMed ID: 32247816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
